PMID- 30362335
OWN - NLM
STAT- MEDLINE
DCOM- 20190205
LR  - 20200225
IS  - 2476-762X (Electronic)
IS  - 1513-7368 (Print)
IS  - 1513-7368 (Linking)
VI  - 19
IP  - 10
DP  - 2018 Oct 26
TI  - A Phase IV Efficacy Study of Formeta Plus Carboplatin as First-Line Treatment of 
      Advanced Non-Squamous, Non-Small Cell Lung Cancer in Iran: An Affordable Price 
      with Clinical Benefit.
PG  - 2973-2978
AB  - Background: This study performed to assess the efficacy and safety of Formeta 
      (generic form of Pemetrexed) plus Carboplatin as first-line chemotherapy in 
      advanced stage, non- squamous, non small cell lung cancer ( NSCLC) in Iran. 
      Methods: This was a post marketing single-arm phase IV efficacy study of Formeta 
      (manufactured by Oncomed.,Czech Republic ) and Carboplatin in chemo-naive 
      advanced non-squamous NSCLC Iranian patients. Patients received up to six cycles 
      of Formeta (500 mg/m2) combined with Carboplatin (area under the curve: AUC 5) 
      every 3 weeks. The primary endpoint was the progression free survival (PFS) and 
      secondary endpoints were safety and overall survival (OS). Results: Fifty-two 
      patients were enrolled between June 2014 to January 2016, and 44 patients were 
      evaluable for both safety and efficacy. Partial and complete responses were 
      achieved in 19 (36.5 %) and 2 (3.8%) patients, respectively as well as stable 
      disease in 8 patients (15.3 %). Median of PFS and OS were 7.9 +/- 1.1 months and 
      12.43+/-0.6 months, respectively. Anemia was the most prevalent adverse events of 
      this regimen. Grades 3 or 4 of adverse events were not observed in any patients. 
      Non-hematologic and other grades of hematologic toxicities were generally mild, 
      and there were no treatment-related deaths. Conclusion: The combination of 
      Formeta and Carboplatin was effective in advanced non-squamous NSCLC and can be a 
      suitable candidate as first-line treatment in these patient's population.
CI  - Creative Commons Attribution License
FAU - Khosravi, Adnan
AU  - Khosravi A
AD  - Tobacco Prevention and Control Research Center, National Research Institute of 
      Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical 
      Sciences, Tehran, Iran. Email: sh_seifi@sbmu.ac.ir
FAU - Salimi, Babak
AU  - Salimi B
FAU - Esfahani-Monfared, Zahra
AU  - Esfahani-Monfared Z
FAU - Seifi, Sharareh
AU  - Seifi S
FAU - Mirtavoos-Mahyari, Hanifeh
AU  - Mirtavoos-Mahyari H
LA  - eng
PT  - Clinical Trial, Phase IV
PT  - Journal Article
DEP - 20181026
PL  - Thailand
TA  - Asian Pac J Cancer Prev
JT  - Asian Pacific journal of cancer prevention : APJCP
JID - 101130625
RN  - 04Q9AIZ7NO (Pemetrexed)
RN  - BG3F62OND5 (Carboplatin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Carboplatin/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Iran
MH  - Lung Neoplasms/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Pemetrexed/*therapeutic use
PMC - PMC6291026
OTO - NOTNLM
OT  - *Non small cell lung cancer
OT  - *carboplatin
OT  - *pemetrexed
OT  - *chemotherapy
OT  - *safety
EDAT- 2018/10/27 06:00
MHDA- 2019/02/06 06:00
PMCR- 2018/03/01
CRDT- 2018/10/27 06:00
PHST- 2018/10/27 06:00 [entrez]
PHST- 2018/10/27 06:00 [pubmed]
PHST- 2019/02/06 06:00 [medline]
PHST- 2018/03/01 00:00 [pmc-release]
AID - APJCP-19-2973 [pii]
AID - 10.22034/APJCP.2018.19.10.2973 [doi]
PST - epublish
SO  - Asian Pac J Cancer Prev. 2018 Oct 26;19(10):2973-2978. doi: 
      10.22034/APJCP.2018.19.10.2973.